Fig. 1. Longitudinal patient timelines for the TRACERx 421 cohort.

The timing of clinical events including treatment, relapse or detection of a new primary and either time of death or latest follow-up is depicted for the 421 patients enrolled into the TRACERx study. Patients are arranged by histology and the presence or absence of a new lesion detected during follow-up. CRUK identifiers are coloured on the basis of whether the patient did not develop a new lesion after surgery (black) or if the first event after surgery was classified as recurrence (dark grey) or a new primary tumour (light grey). The overall patient stage at surgery and smoking status is depicted alongside metrics of ITH measured using multiregion WES of surgically excised samples including mutational ITH (the fraction of subclonal mutations), SCNA ITH (the fraction of the aberrant genome with subclonal SCNAs) and the estimated number of truncal and subclonal WGDs using our method ParallelGDDetect.